Увійти

Готові списки джерел за темами / 18F-NaF

Добірка наукової літератури з теми "18F-NaF"

Автор: Grafiati

Опубліковано: 28 вересня 2022

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "18F-NaF".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

Статті в журналах
Дисертації
Частини книг
Тези доповідей конференцій

Статті в журналах з теми "18F-NaF":

1

Weinberg, Benjamin Adam, Maria Liza Lindenberg, Karen A. Kurdziel, Seth M. Steinberg, David J. Liewehr, Kattie Khadar, Yolanda McKinney, Peter L. Choyke, and Andrea Borghese Apolo. "Assessment of bone metastases in patients (pts) with urothelial carcinoma using 18F-sodium fluoride PET/CT (18F-NaF) versus 18F-fluorodeoxyglucose PET/CT (18F-FDG)." Journal of Clinical Oncology 32, no. 4_suppl (February 1, 2014): 329. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.329.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

329 Background: 18F-NaF has shown improved sensitivity for bone imaging when compared to conventional planar imaging or SPECT/CT using 99mTc-MDP. We compared the number of bone lesions detected on 18F-NaF versus 18F-FDG in urothelial cancer pts with known bone metastases undergoing treatment. Methods: Pts enrolled in a prospective single-arm phase II study of cabozantinib underwent 18F-NaF and 18F-FDG scans at baseline and at 8 weeks of therapy. In a lesion-based analysis independently confirmed by a nuclear medicine physician, abnormal foci of radiotracer uptake were categorized by location (skull, spine, pelvis, thorax, or long bones) and by disease state (benign, malignant, or indeterminate). A patient-based analysis was performed to determine if findings indicated disease progression, stable disease, or improvement of disease, based on the number of lesions and standardized uptake values (SUVs). Results: 294 total bone lesions were identified at baseline in 10 pts (8 male and 2 female, ages 44-73). 18F-NaF identified more lesions than 18F-FDG at baseline, 294 vs. 119. In a paired analysis, the median difference was 11.5 more lesions detected per patient on 18F-NaF vs. 18F-FDG (by Wilcoxon signed-rank test, p = 0.023). More total thoracic bone lesions at baseline, 100 vs. 23, were also detected on 18F-NaF vs. 18F-FDG, median 6.5 vs. 1.0 with a median difference of 6 more lesions per patient on 18F-NaF (p = 0.016). 18F-NaF also detected more skull lesions at baseline, 19 vs. 1, which was clinically but not statistically significant (p = 0.250). There was general concordance in the patient-based analysis; only 1 18F-NaF scan demonstrated progressive disease while its corresponding 18F-FDG scan showed stable disease. Conclusions:18F-NaF identified more lesions than 18F-FDG at baseline, making it a good staging exam. However, there was agreement between 18F-NaF and 18F-FDG in terms of tumor response in almost all the follow-up scans. Therefore, although a greater number of bone lesions are seen in 18F-NaF compared with 18F-FDG, the clinical significance in assessing treatment response remains to be determined. Clinical trial information: NCT01688999.

2

Wang, Dong, YiYang Yang, ZhenPei Zeng, Jing Ye, ChengMao Guo, ShiSang Huang, XuFeng Guo, and JingXing Xiao. "Comparison of Bone Metastases between 18F-NaF PET/CT, 18F-NaF PET, and Planar 99mTc-MDP Bone Scintigraphy in Patients with Newly Diagnosed Nasopharyngeal Carcinoma." Contrast Media & Molecular Imaging 2022 (April 13, 2022): 1–8. http://dx.doi.org/10.1155/2022/5975338.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Purpose. Our study aims to compare the diagnostic value of 18F-NaF positron emission tomography-computed tomography (PET/CT), 18F-NaF PET, and planar 99mTc-MDP bone scintigraphy for detection of bone metastases in patients with newly diagnosed nasopharyngeal carcinoma (NPC). Methods. Our study retrospectively analyzed 58 patients with pathologically proven NPC. They all underwent both 18F-NaF PET/CT and planar 99mTc-MDP bone scintigraphy within a 7-day interval. Bone metastases were confirmed by follow-up using PET/CT, contrast-enhanced computed tomography (CT), and magnetic resonance imaging (MRI). These three examinations were compared using per-patient-based analysis and per-lesion-based analysis. Results. 19 patients (32.7%) were classified as having bone metastatic disease in their final diagnosis. The patient-based diagnostic performances (sensitivity, specificity, and overall accuracy) were as follows: 18F-NaF PET/CT (100%, 92.3%, and 94.8%), 18F-NaF PET (100%, 53.8%, and 69.0%), and planar 99mTc-MDP bone scintigraphy (78.9%, 74.4%, and 75.9%). The overall accuracy of 18F-NaF PET/CT was significantly more favorable compared to 18F-NaF PET ( p = 0.002 ) and to planar 99mTc-MDP bone scintigraphy ( p = 0.044 ). The lesion-based diagnostic performances (sensitivity, specificity, and overall accuracy) were as follows: 18F-NaF PET/CT (98.5%, 93.9%, and 96.6%), 18F-NaF PET (98.5%, 57.1%, and 81.1%), and planar 99mTc-MDP bone scintigraphy (69.9%, 85.7%, and 76.4%). Conclusion. 18F-NaF PET/CT outperforms 18F-NaF PET or planar 99mTc-MDP bone scintigraphy in detecting bone metastases with newly diagnosed NPC on a patient-based and lesion-based analysis.

3

Kwiecinski, Jacek, Piotr J. Slomka, Marc R. Dweck, David E. Newby, and Daniel S. Berman. "Vulnerable plaque imaging using 18F-sodium fluoride positron emission tomography." British Journal of Radiology 93, no. 1113 (September 1, 2020): 20190797. http://dx.doi.org/10.1259/bjr.20190797.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Positron emission tomography (PET) with 18F-sodium fluoride (18F-NaF) has emerged as a promising non-invasive imaging modality to identify high-risk and ruptured atherosclerotic plaques. By visualizing microcalcification, 18F-NaF PET holds clinical promise in refining how we evaluate coronary artery disease, shifting our focus from assessing disease burden to atherosclerosis activity. In this review, we provide an overview of studies that have utilized 18F-NaF PET for imaging atherosclerosis. We discuss the associations between traditional coronary artery disease measures (risk factors) and 18F-NaF plaque activity. We also present the data on the histological validation as well as show how 18F-NaF uptake is associated with plaque morphology on intravascular and CT imaging. Finally, we discuss the technical challenges associated with 18F-NaF coronary PET highlighting recent advances in this area.

4

Sachpekidis, Christos, Annette Kopp-Schneider, Maximilian Merz, Anna Jauch, Marc-Steffen Raab, Hartmut Goldschmidt, and Antonia Dimitrakopoulou-Strauss. "Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?" Cancers 12, no. 5 (May 23, 2020): 1335. http://dx.doi.org/10.3390/cancers12051335.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

There is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used 18F-fluorodeoxyglucose (18F-FDG). Sodium fluoride (18F-NaF) is a highly sensitive tracer of bone reconstruction, evolving as an important imaging agent for the assessment of malignant bone diseases. We attempted to investigate for the first time the prognostic significance of 18F-NaF PET/CT in newly diagnosed, symptomatic MM patients planned for autologous stem cell transplantation (ASCT). Forty-seven patients underwent dynamic and static PET/CT with 18F-NaF before treatment. After correlation with the respective findings on CT and 18F-FDG PET/CT that served as reference, the 18F-NaF PET findings were compared with established factors of high-risk disease, like cytogenetic abnormalities as well as bone marrow plasma cell infiltration rate. Furthermore, the impact of 18F-NaF PET/CT on progression-free survival (PFS) was analyzed. Correlation analysis revealed a moderate, significant correlation of the 18F-NaF parameters SUVaverage and K1 in reference tissue with bone marrow plasma cell infiltration rate. However, no significant correlation was observed regarding all other 18F-NaF PET parameters. Survival analysis revealed that patients with a pathologic 18F-NaF PET/CT have a shorter PFS (median = 36.2 months) than those with a physiologic scan (median = 55.6 months) (p = 0.02). Nevertheless, no quantitative 18F-NaF parameter could be shown to adversely affect PFS. In contrast, the respective analysis for quantitative dynamic 18F-FDG PET/CT revealed that the parameters SUVmax, fractional blood volume (VB), k3 and influx from reference tissue as well as SUVaverage from MM lesions had a significant negative impact on patient survival. The herein presented findings highlight the rather limited role of 18F-NaF PET/CT as a single PET approach in MM.

5

Kim, Joseph W., Maria Liza Lindenberg, William L. Dahut, James L. Gulley, Ravi A. Madan, Lauren V. Wood, Yolanda McKinney, Peter L. Choyke, Karen A. Kurdziel, and Andrea Borghese Apolo. "A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10589. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10589.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

10589 Background: We evaluated the clinical utility of 18F-sodium fluoride PET/CT bone scan (18F-NaF) in the detection of bone metastases in patients (pts) with prostate cancer in comparison with Technetium-99m MDP bone scan (TcBS). Methods: In a prospective study, from October 2010-December 2011, 30 prostate cancer pts (ages 51-79), 21 with known bone metastases and 9 without known bone metastases, had18F-NaF and a TcBS performed. Abnormal foci of uptake on both TcBS and 18F-NaFwere classified as benign, malignant or indeterminate. Benign lesions included uptake in the joints and linear uptake at the endplates of the vertebral bodies consistent with degenerative changes. Malignant uptake on 18F-NaF scans was confirmed by characteristic osteoblastic features on CT. All TcBS and 18F-NaF were reviewed by an experienced nuclear medicine physician. For the patient-based analysis, scan results were categorized as positive (POS) = any malignant lesion; indeterminate (IND) = not distinctly malignant or benign; negative (NEG) = benign lesions only. Results: In the lesion-based analysis, 21 of 30 (70%) pts had more malignant lesions identified on 18F-NaF than on TcBS. The mean number of additional malignant lesions per patient on 18F-NaF vs TcBS was 4. Eight of the 30 pts had same number of malignant lesions identified in both studies. One of 30 pts had one less malignant lesion identified on 18F-NaF than on TcBS. CT correlation by 18F-NaF PET/CT of this particular lesion did not confirm osteoblastic feature. Malignant lesion distribution on 18F-NaF included: spine (28%), thorax (26%), pelvis (24%), long bones (13%) and skull (10%). In the patient-based analysis, 24 pts (80%) were POS by 18F-NaF, of whom 14 pts were POS, 8 were IND, and 2 were NEG by corresponding TcBS; in the 4 pts with NEG 18F-NaF, zero were POS, 2 were IND and 2 were NEG by corresponding TcBS. Conclusions: 18F-NaF identified more malignant lesions than TcBS. 18F-NaF may also add useful information in the management of advanced prostate cancer pts with and without known bone metastases.

6

Zhang, Yin, Yue Chen, Zhanwen Huang, Li Zhang, Qiang Wan, and Lei Lei. "Comparison of 18F-NaF PET/CT and 18F-FDG PET/CT for Detection of Skull-Base Invasion and Osseous Metastases in Nasopharyngeal Carcinoma." Contrast Media & Molecular Imaging 2018 (September 5, 2018): 1–7. http://dx.doi.org/10.1155/2018/8271313.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Our study aimed at comparing the diagnostic value of 18F-NaF positron emission tomography-computed tomography (PET/CT) and 18F-fluorodeoxyglucose (FDG) PET/CT for detection of skull-base invasion and osseous metastases in patients with nasopharyngeal carcinoma (NPC). Our study retrospectively analyzed 45 patients with pathologically proven NPC. They all underwent both 18F-NaF PET/CT and 18F-FDG PET/CT within a 7-day interval. Bone metastases were confirmed by follow-up using PET/CT, enhance-contrast computed tomography (CT), and magnetic resonance image (MRI). These two examinations were compared using per-patient-based analysis and per-lesion-based analysis. 18F-NaF PET/CT detected 27 patients with skull-base invasion, whereas 18F-FDG PET/CT detected 17 patients. 18F-NaF PET/CT and 18F-FDG PET/CT differed significantly in diagnosing skull-base invasion (p=0.02) and sensitivity (p=0.008). The sensitivity, specificity, and agreement rate of 18F-NaF PET/CT for detecting bone metastatic lesions were 98.3%, 65.7%, and 92.9%, respectively; these values were 42.9%, 97.1%, and 51.9%, respectively, for 18F-FDG PET/CT. 18F-NaF PET/CT and 18F-FDG PET/CT differed significantly in the number of osseous metastases detected (t=2.45, p=0.18) sensitivity (p<0.0001) and specificity (p=0.003). In patients with nasopharyngeal carcinoma, 18F-NaF PET/CT assessed invasion of the skull base better and detected more osseous metastases than 18F-FDG PET/CT.

7

Lapa, Paula, Tiago Saraiva, Rodolfo Silva, Margarida Marques, Gracinda Costa, and João Pedroso Lima. "Superioridade da PET/CT com FNa-F18 na Deteção de Metástases Ósseas quando Comparada com Outros Métodos de Diagnóstico por Imagem." Acta Médica Portuguesa 30, no. 1 (January 31, 2017): 53. http://dx.doi.org/10.20344/amp.7818.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction: The 18F-NaF positron emission tomography/computed tomography is being considered as an excellent imaging modalityfor bone metastases detection. This ability was compared with other imaging techniques.Material and Methods: We retrospectively evaluated 114 patients who underwent 18F-NaF positron emission tomography/ computed tomography. Of these, 49 patients also had bone scintigraphy, 61 18F-FDG positron emission tomography/computed tomography and 10 18F-FCH positron emission tomography/computed tomography. We identified the technique that detected the largest number of bone metastases. For the detection of skeletal metastases with the 18F-NaF positron emission tomography/computed tomography study,the contribution of the positron emission tomography component was compared with the contribution of the computed tomography component. Cases in which 18F-NaF positron emission tomography/computed tomography and bone scintigraphy required further additional tests for diagnosis clarification were registered.Results: The 18F-NaF positron emission tomography/computed tomography was superior to bone scintigraphy in 49% of the patients(p < 0.001); it was superior to 18F-FDG positron emission tomography/computed tomography in 59% of the patients (p < 0.001) and it was superior to 18F-FCH positron emission tomography/computed tomography in 40% of the patients (p < 0.001). None of the compared imaging techniques were superior to 18F-NaF positron emission tomography/computed tomography. The positron emission tomography component was superior to computed tomography in 35% of the cases (p < 0.001). Further investigation was suggested in only 3.5% of patients who underwent 18F-NaF positron emission tomography/computed tomography (45% for bone scintigraphy) (p < 0.001).Discussion: As with other authors, our experience also confirms that 18F-NaF positron emission tomography/computed tomography is an excellent imaging modality for the detection of bone metastases, detecting lesions in more patients and more lesions per patient.Conclusion: The 18F-NaF positron emission tomography/computed tomography showed a superior ability for the detection of bone metastases when compared with bone scintigraphy, 18F-FDG positron emission tomography/computed tomography and 18F-FCH positron emission tomography/computed tomography.

8

Kwiecinski, Jacek, Damini Dey, Sebastien Cadet, Sang-Eun Lee, Balaji Tamarappoo, Yuka Otaki, Phi T. Huynh, et al. "Predictors of 18F-sodium fluoride uptake in patients with stable coronary artery disease and adverse plaque features on computed tomography angiography." European Heart Journal - Cardiovascular Imaging 21, no. 1 (June 18, 2019): 58–66. http://dx.doi.org/10.1093/ehjci/jez152.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract Aims In patients with stable coronary artery disease (CAD) and high-risk plaques (HRPs) on coronary computed tomography angiography (CTA), we sought to define qualitative and quantitative CTA predictors of abnormal coronary 18F-sodium fluoride uptake (18F-NaF) by positron emission tomography (PET). Methods and results Patients undergoing coronary CTA were screened for HRP. Those who presented with ≥3 CTA adverse plaque features (APFs) including positive remodelling; low attenuation plaque (LAP, <30 HU), spotty calcification; obstructive coronary stenosis ≥50%; plaque volume >100 mm3 were recruited for 18F-NaF PET. In lesions with stenosis ≥25%, quantitative plaque analysis and maximum 18F-NaF target to background ratios (TBRs) were measured. Of 55 patients, 35 (64%) manifested coronary 18F-NaF uptake. Of 68 high-risk lesions 49 (70%) had increased PET tracer activity. Of the APFs, LAP had the highest sensitivity (39.4%) and specificity (98.3%) for predicting 18F-NaF uptake. TBR values were higher in lesions with LAP compared to those without [1.6 (1.3–1.8) vs. 1.1 (1.0–1.3), P = 0.01]. On adjusted multivariable regression analysis, LAP (both qualitative and quantitative) was independently associated with plaque TBR [LAP qualitative: β = 0.47, 95% confidence interval (CI) 0.30–0.65; P < 0.001] and (LAP volume: β = 0.20 per 10 mm3, 95% CI 0.13–0.27; P < 0.001). Conclusion In stable CAD patients with HRP, LAP is predictive of 18F-NaF coronary uptake, but 18F-NaF is often seen in the absence of LAP. If 18F-NaF uptake is shown to be associated with adverse outcomes and becomes clinically used, the presence of LAP may define patients who would not benefit from the added testing.

9

Kwiecinski, Jacek, Martin Lyngby Lassen, and Piotr J. Slomka. "Advances in Quantitative Analysis of 18F-Sodium Fluoride Coronary Imaging." Molecular Imaging 2021 (January 13, 2021): 1–9. http://dx.doi.org/10.1155/2021/8849429.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

18F-sodium fluoride (18F-NaF) positron emission tomography (PET) has emerged as a promising noninvasive imaging tool for the assessment of active calcification processes in coronary artery disease. 18F-NaF uptake colocalizes to high-risk and ruptured atherosclerotic plaques. Most recently, 18F-NaF coronary uptake was shown to be a robust and independent predictor of myocardial infarction in patients with advanced coronary artery disease. In this review, we provide an overview of the advances in coronary 18F-NaF imaging. In particular, we discuss the recently developed and validated motion correction techniques which address heart contractions, tidal breathing, and patient repositioning during the prolonged PET acquisitions. Additionally, we discuss a novel quantification approach—the coronary microcalcification activity (which has been inspired by the widely employed method in oncology total active tumor volume measurement). This new method provides a single number encompassing 18F-NaF activity within the entire coronary vasculature rather than just information regarding a single area of most intense tracer uptake.

10

Glasgow, Krystle W. "18F-NaF PET/CT." Journal of Nuclear Medicine Technology 49, no. 2 (June 2021): 105–6. http://dx.doi.org/10.2967/jnmt.121.262379.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "18F-NaF":

1

Omarjee, Loukman. "Atteintes Cardiovasculaires du Pseudoxanthome Élastique : Aspects Physiopathologiques et Stratégies Thérapeutiques." Thesis, Angers, 2019. https://dune.univ-angers.fr/documents/dune15886.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

L’objectif global de cette thèse était d’étudier, à partir de la cohorte des patients du centre de référence PXE du CHU d’Angers, différente aspects du phénotype cardiovasculaire (CV) du PXE. Ainsi, dans un premier travail, nous avons pu montrer dans l’étude GOCAPXE, que les calcifications ectopiques seraient un processus actif pouvant être détecté par une imagerie moléculaire utilisant un traceur spécifique de l’activité ostéoblastique, le 18-Fluorure de Sodium (18F-NaF); que ce processus était détectable avant même que ces calcifications ne soient visibles par les techniques d’imageries classiques; que ce processus était localisé aux zones habituellement lésées dans le PXE : les plis de flexion et le cou pour la peau et l’artère fémorale superficielle pour le vaisseau. Cette technique mériterait d’être validée dans une étude longitudinale et son rôle en tant biomarqueur diagnostique et de suivi serait ainsi envisageable. Le deuxième travail de cette thèse a été d’étudier les conséquences morphologiques et fonctionnelles d’une augmentation chronique de la pression artérielle chez les patients PXE. Cette question était pertinente car dans la littérature, la question d’une hypertension artérielle (HTA) chez les PXE reste controversée. Nous avons ainsi montré pour la première fois que dans un modèle d’HTA induite par le Deoxycorticostérone (DOCA)-Salt chez la souris Abcc6-/- cette augmentation de la pression artérielle induisait un remodelage CV avec à la fois de la fibrose et des calcifications dystrophiques. Les résultats de cette étude suggèrent la nécessité d’un contrôle optimal de la pression artérielle chez les patients PXE. Le troisième travail de cette thèse a été de caractériser une lésion de la carotide interne détectée avec une fréquence élevée dans la cohorte angevine. Nous avons pu montrer que cette anomalie était une hypoplasie de la carotide interne d’origine probablement congénitale. Chez les patients de la cohorte angevine, cette lésion était associée à des anévrismes intracrâniens mais nous n’avons pas retrouvé d’association avec la survenue d’accident vasculaire cérébral. Ainsi, les résultats de cette étude invitent les praticiens prenant en charge des patients PXE à la rechercher systématiquement dans le bilan vasculaire d’un patient PXE. Si une telle lésion est retrouvée, une imagerie vasculaire intracrânienne devrait être proposée à la recherche d’anévrismes et leur prise en charge discuté en concertation multidisciplinaire. Enfin, le dernier travail a permis de montrer qu’un traitement systémique par le Thiosulfate de Sodium (STS), utilisé dans la calciphylaxie rénale, était efficace sur la régression des calcifications artérielles et cutanées chez une jeune garçon ayant un phénotype CV gravissime résultant de la combinaison délétères de plusieurs gènes pathogènes du spectre PXE Ce traitement mériterait d’être validé dans un essai thérapeutique chez l’humain mais aussi la démonstration de ses mécanismes d’action dans le modèle murin Abcc6-/-. Nous suggérons d’utiliser ce traitement en cas de PXE sévère et rapidement progressif notamment sur le plan vasculaire. Au terme de ce travail de thèse, nous avons montré que le gène ABCC6 était impliqué dans le remodelage vasculaire à la fois au niveau développemental (Hypoplasie Carotidienne) mais aussi acquis (Fibrose, Calcification Cardiaque Dystrophique). Nous avons montré aussi que les calcifications dans le PXE étaient tissus et localisations spécifiques, que ces calcifications étaient actives. Enfin nous avons ouvert la porte à un traitement des formes graves du PXE avec le Thiosulfate de Sodium. Une approche thérapeutique multimodale ciblant plusieurs mécanismes concourant aux calcifications seraient judicieux à évaluer dans les futurs essais cliniques
Since the discovery of the ABCC6 gene in 2000, mutations are at the origin of PseudoxanthomeElastic (PXE), knowledge of genetics, pathophysiology, phenotypic characterizations have has mademajor advances, notably with the Discovery in 2013 of the fundamental role of Pyrophosphateinorganic (PPi) as a deficient anti‐calcifying factor in patients. The overall goal of this thesis was tostudy, from the cohort of patients at the center of PXE reference of the CHU d'Angers, differentaspects of cardiovascular phenotype (CV) of PXE. Thus, in a first work, we were able to show in thestudy GOCAPXE, that ectopic calcifications would be a active process that can be detected by imagingUsing a specific activity tracer Osteoblastic, 18‐sodium fluoride (18F‐NaF); that this process wasdetectable even before these calcifications are not visible by conventional imaging techniques; thatthis process was localized to areas usually injured in the PXE: flexion folds and neck for skin and thesuperficial femoral artery for the vessel. This technique should be validated in a study longitudinaland its role as a diagnostic biomarker In this way, monitoring and monitoring could be considered.The second work of this thesis was to study the morphological consequences and functional of achronic increase in blood pressure in PXE patients. This question was relevant because in theliterature, the question of a high blood pressure (hypertension) in PXE remains controversial. Wehave thus shown for the first time that in a model of HTA induced by the Deoxycorticosterone(DOCA)‐Salt in Abcc6‐/‐ this increase in blood pressure led to a CV remodeling with both fibrosis andcalcifications dystrophic. The results of this study suggest need for optimal control of blood pressurein patients. The third work of this thesis was to characterize a lesion of the internal carotid detectedwith high frequency in the Angevine cohort. We have could show that this abnormality washypoplasia of the Probably congenital internal carotid. In the patients of the angevine cohort, thislesion was associated with intracranial aneurysms but we have not found in association with theoccurrence of vascular accident brain. Thus, the results of this study invite practitioners supportingPXE patients to search for it systematically in the vascular balance of a PXE patient. If such a lesion isfound, vascular imaging Intracranial should be proposed to research Aneurysms and theirmanagement discussed in consultation multidisciplinary. Finally, the latest work has made it possibleto show that systemic treatment with Thiosulphate Sodium (STS), used in renal calciphylaxia, waseffective on the regression of arterial calcifications and skin in a young boy with a phenotype CVGravel resulting from the deleterious combination of several pathogenic genes of the PXE spectrumThis treatment would deserve be validated in a human therapeutic trial but also the demonstrationof its mechanisms of action in the Abcc6‐/‐murin model. We suggest using this treatment for severeand rapidly progressive PXE especially on the vascular plane.At the end of this thesis work, we showed that the ABCC6 gene was involved in vascular remodelingat both at the developmental level (Carotid Hypoplasia) but also acquired (Fibrosis, CardiacCalcification Dystrophic). We also showed that calcifications in PXE were tissues and locationsspecific, that these calcifications were active. Finally we have opened the door to a treatment ofsevere forms of PXE with Sodium Thiosulphate. An approach multimodal therapy targeting multiplemechanisms this would be useful to evaluate in future clinical trials

Частини книг з теми "18F-NaF":

1

Calabria, Ferdinando, and Orazio Schillaci. "18F-NaF." In Radiopharmaceuticals, 89–98. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-27779-6_5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Ballinger, James R. "Sodium 18F-Fluoride (NaF)." In PET Radiopharmaceuticals, 4–5. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-10271-4_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Usmani, Sharjeel, Kanhaiyalal Agrawal, Abdulredha Esmail, Fahad Marafi, and Gopinath Gnanasegaran. "18F-NaF PET/CT Imaging." In PET/CT Imaging, 109–24. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-75476-1_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Lee, Won Woo, and Yong-Whee Bahk. "18F-NaF PET/CT in Bone and Joint Diseases." In Combined Scintigraphic and Radiographic Diagnosis of Bone and Joint Diseases, 539–52. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-2759-8_22.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Kairemo, Kalevi, and Homer A. Macapinlac. "Treatment Response Evaluation of Bone Metastases Using 18F-NaF." In Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology, 101–17. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-68858-5_9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Cook, Gary J. R., and Sharjeel Usmani. "18F-FDG PET-CT and 18F-NaF in Treatment Response Evaluation: Bone Metastases and Bone Tumours." In Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology, 403–17. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-68858-5_24.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Wu, L., S. A. Kwee, M. Li, X. Peng, L. Xie, Z. Lin, H. Wang, and Y. Kuang. "18F-NaF PET/CT-directed dose escalation in stereotactic body radiotherapy for spine oligometastases from prostate cancer." In IFMBE Proceedings, 565–68. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19387-8_138.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "18F-NaF":

1

Douhi, Abdelillah, Mamdouh S. Al-Enezi, Abdelouahed Khalil, Tamas Fulop, Eric Turcotte, Michel Nguyen, and M'hamed Bentourkia. "Coupling of 18F-NaF and 18F-FDG PET/CT Dynamic Imaging for the Detection of Arterial Inflammation." In 2021 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC). IEEE, 2021. http://dx.doi.org/10.1109/nss/mic44867.2021.9875576.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Karakatsanis, Nicolas A., Ronan Abgral, Gilles Boeykens, Marc R. Dweck, Philip M. Robson, Maria Giovanna Trivieri, Claudia Calgano, Charalampos Tsoumpas, and Zahi A. Fayad. "18F-FDG:18F-NaF PET/MR multi-parametric imaging with kinetics-based bone segmentation for enhanced dual-tracer PET quantification." In 2016 IEEE Nuclear Science Symposium, Medical Imaging Conference and Room-Temperature Semiconductor Detector Workshop (NSS/MIC/RTSD). IEEE, 2016. http://dx.doi.org/10.1109/nssmic.2016.8069386.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Brinkevich, D. I., S. D. Brinkevich, H. I. Kiyavitskaya, and A. N. Kiyko. "BETA-RADIATING RADIONUCLIDES FORMED IN A WATER TARGET OF A COMMERCIAL CYCLOTRON." In SAKHAROV READINGS 2021: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2021. http://dx.doi.org/10.46646/sakh-2021-2-248-252.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The accumulation of в-emitting radionuclides during irradiation of a liquid target of the Cyclone 18/9 HC commercial cyclotron and the production of radiopharmaceuticals (RP) based on 18F was studied by liquid scintillation spectroscopy. It is shown that with prolonged use of the target in the в-spectra of regenerated water [18O] H2O and ready-made RP [18F] NaF, in addition to the maximum due to tritium, a number of maxima appear in both the low-and high-energy parts of the spectrum. Storage for 3 months leads to a significant transformation of the spectra - the intensity of the low-energy wing of the regenerated water spectrum decreases sharply, the maximum in the 300 channel region disappears, while the intensity of the high-energy wing decreases not so dramatically. It was found that the tritium content in the regenerated water can be reliably estimated only after storage for 3 months.

4

Al-Enezi, Mamdouh S., Eric Lavallee, Eric Turcotte, Abdelouahed Khalil, Tamas Fulop, Michel Nguyen, and M'hamed Bentourkia. "Assessment of Arterial Wall Calcification with CT and Micro-Calcification with 18F-NaF PET." In 2021 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC). IEEE, 2021. http://dx.doi.org/10.1109/nss/mic44867.2021.9875685.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Bell, Michael, Joanna Koch Paszkowski, John Wright, Lucinda Craggs, Charalampos Tsoumpas, and Marc Bailey. "Tracing Microcalcification Development in the Porcine Pancreatic Elastase Murine Model of Abdominal Aortic Aneurysm Using [18F]-NAF." In 70th International Congress of the European Society for Cardiovascular and Endovascular Surgery and 7th International Meeting on Aortic Diseases. Thieme Medical Publishers, Inc., 2022. http://dx.doi.org/10.1055/s-0042-1750913.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

RUIZ GARCIA DE ALMEIDA, RICARDO, Celso Dario Ramos, and ANA EMÍLIA TEIXEIRA BRITO. "PET/CT COM FDG-18F VERSUS PET/CT COM NaF-18F NO DIAGNÓSTICO DE METÁSTASES ÓSSEAS EM PACIENTES COM CÂNCER DE MAMA E CINTILOGRAFIA ÓSSEA INCONCLUSIVA." In XXV Congresso de Iniciação Cientifica da Unicamp. Campinas - SP, Brazil: Galoa, 2017. http://dx.doi.org/10.19146/pibic-2017-78113.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.